The Japanese Version of the EORTC Quality of Life Questionnaire

  • G. Tóth
  • M. Tsukuda
Reference work entry


This Chapter summarizes  quality of life (QoL) questionnaires for various types of cancer. Most of the patient-centered QoL measurement tools have been developed in English-speaking cultures. Thus, it has been a vitally important question whether or not these questionnaires could be used in other cultures – like African and Eastern countries – and cross a broad cultural divide.

The  European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaires (QLQ) were continuously developed and used since 1993 first in European countries and later on worldwide in international trials. Therefore, a standardized translation and cultural adaptation procedure was also developed by the EORTC Quality of Life Group (QLG) to respond to the international interest in non-English speaking countries and cultures. To date, the EORTC QLQ 30-item core questionnaire (QLQ-C30) has been translated and validated into more than 60 languages and its cancer site/type specific modules (e.g., Palliative care, Breast-, Cervix-, Head and Neck cancer etc.) are under further translation and validation process. Translations and cultural validations include all major Western, and many African and Asian languages.

The aim of this Chapter is to give a brief account of the existing EORTC QLQ modules and their cultural validation (linguistic and psychometric validation) into Japanese language for use in cancer patients. We give an overview of the translation problems and different priorities of social issues between Western and Eastern – in our case Japanese – culture.


Japanese Version Supplementary Module Japanese Language Linguistic Validation Asian Cultural Context 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

List of Abbreviations:


Action concerning Protection of Personal Information


breast cancer module


Brahma gene


palliative care core questionnaire


30-item cancer core


Complete Response


cervical cancer module


Eastern Cooperative Oncology Group Performance Status Rating scale


Epidermal Growth Factor Receptor


European Organization for Research and Treatment of Cancer


Functional Assessment of Cancer Therapy-General


Functional Assessment of Cancer Therapy-Head and Neck cancer subscale


Functional Living Index-Cancer


General Health Questionnaire


35-item module for Head and Neck cancer


Health-related Quality of Life


Intensity-Modulated Radiation Therapy


cancer in-patient satisfaction with care questionnaire


Karnofsky Performance Scale


lung cancer module


multiple myeloma module


esophageal cancer module


ovarian cancer module


Profile of Mood States


Performance Status Scale for Head and Neck Cancer


Quality of Life Study Group


Quality of Life Questionnaire


Quality of Life Unit


Quality of Life


Quality of Life Questionnaire for Cancer Patients Treated with Anti-Cancer Drugs


Quality of Life-Radiation Therapy Instrument with Head and Neck Module


Medical Outcomes Study 36-Item Short-Form Survey




gastric cancer module




University of Washington Quality of Life Questionnaire for Head and Neck Cancer


World Health Organization Quality of Life 26


  1. Aaronson NK. (1998). Eur J Cancer. 34: 767–769.PubMedCrossRefGoogle Scholar
  2. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, et al. (1993). J Natl Cancer Inst. 85: 365–376.PubMedCrossRefGoogle Scholar
  3. Aaronson NK, Bullinger M, Ahmedzai S. (1988). Cancer Res. 111: 231–249.Google Scholar
  4. Bjordal K, de Graeff A, Fayers PM, Hammerlid E, van Pottelsberghe C, et al. (2000). Eur J Cancer. 36: 1796–1807.PubMedCrossRefGoogle Scholar
  5. Bjordal K, Kaasa S. (1992). Acta Oncol. 31: 311–321.PubMedCrossRefGoogle Scholar
  6. Bonomi AE, Cella DF, Hahn EA, Bjordal K, Sperner-Unterweger B, et al. (1996). Qual Life Res. 5: 309–320.PubMedCrossRefGoogle Scholar
  7. Bullinger M, Anderson R, Cella D, Aaronson N. (1993). Qual Life Res. 2: 451–459.PubMedCrossRefGoogle Scholar
  8. Cheung YB, Thumboo J. (2006). Pharmacoeconomics. 24: 643–650.PubMedCrossRefGoogle Scholar
  9. Chie WC, Hong RL, Lai CC, Ting LL, Hsu MM. (2003). Qual Life Res. 12: 93–98.PubMedCrossRefGoogle Scholar
  10. Cull A, Sprangers MAG, Aaronson NK, Bjordal K, West K, et al. (2002). European Organization for Research and Treatment of Cancer quality of life study group translation procedure, 2nd ed. EORTC Quality of Life Group, Brussels.Google Scholar
  11. Eguchi K. (1995). In: Urushizaki I (ed.) Guidebook of Quality of Life Assessment and Questionnaires. Cancer and Chemotherapy Publishers INC, Tokyo, pp. 23–29.Google Scholar
  12. Einhorn LH. (2003). Support Care Cancer. 11: 620–622.PubMedCrossRefGoogle Scholar
  13. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, et al. (2001). EORTC QLQ-C30 Scoring Manual, 3rd ed. EORTC Quality of Life Group, Brussels.Google Scholar
  14. Fayers PM, Machin D. (2000). Quality of Life: Assessment, Analysis and Interpretation. Wiley, New York/Singapore.Google Scholar
  15. Fukuhara S, Bito S, Green J, Hsiao A, Kurokawa K. (1998). J Clin Epidemiol. 51: 1037–1044.PubMedCrossRefGoogle Scholar
  16. Fumimoto H, Kobayashi K, Chang CH, Eremenco S, Fujiki Y, et al. (2001). Qual Life Res. 10: 701–709.PubMedCrossRefGoogle Scholar
  17. Gotay CC, Wilson M. (1998). Eval Health Prof. 21: 157–178.PubMedCrossRefGoogle Scholar
  18. Groenvold M, Klee MC, Sprangers MA, Aaronson NK. (1997). J Clin Epidemiol. 50: 441–450.PubMedCrossRefGoogle Scholar
  19. Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S. (1995). J Clin Oncol. 13: 1249–1254.PubMedGoogle Scholar
  20. Kaasa S. (1992). Oncology. 49: 289–294.PubMedCrossRefGoogle Scholar
  21. Karasawa K, Sasaki T, Okawa T, Takahashi T, Hayakawa K, et al. (2003). J Oncol Manag. 12: 18–24.PubMedGoogle Scholar
  22. Karnofsky DA, Burchemajh JH. (1949). In: McLeod CM (ed.) Evaluation of Chemotherapeutic Agents. Columbia University Press, New York, pp. 191–205.Google Scholar
  23. Kobayashi K, Takeda F, Teramukai S, Gotoh I, Sakai H. et al. (1998). Eur J Cancer. 34: 810–815.PubMedCrossRefGoogle Scholar
  24. Koller M, Aaronson NK, Blazeby J, Bottomley A, Dewolf L, et al. (2007). Eur J Cancer. 43: 1810–1820.PubMedCrossRefGoogle Scholar
  25. Kurihara M, Shimizu H, Tsuboi K, Kobayashi K, Murakami M, et al. (1999). Psychooncology. 8: 355–363.PubMedCrossRefGoogle Scholar
  26. List MA, D'Antonio LL, Cella DF, Siston A, Mumby P, et al. (1996). Cancer. 77: 2294–2301.PubMedCrossRefGoogle Scholar
  27. Matsui K, Lie RK. (2007). Eubios J Asian Int Bioeth. 17: 41–49.Google Scholar
  28. Matsumoto T, Ohashi Y, Morita S, Kobayashi K, Shibuya M, et al. (2002). Qual Life Res. 11: 483–493.PubMedCrossRefGoogle Scholar
  29. Nakagawa Y, Daibo I. (1985). An Introduction to Mental Health Measurement: Japanese Version of the General Health Questionnaire (GHQ). Nihon Bunka Kagakusha Co., Tokyo.Google Scholar
  30. Nishi G. (2001). Japanese Step by Step: An Innovative Approach to Speaking and Reading Japanese. McGraw-Hill, New York, NY.Google Scholar
  31. Nomura K. (ed.) (2005). Cancer Statistics in Japan 2005. Vital and Health Statistics Division, Statistics and Information Department, Minister’s Secretariat, Ministry of Health, Labour and Welfare, Tokyo.Google Scholar
  32. Ohno Y, Nakamura T, Murata K, Tsukuma H, Ajiki W, et al. (2004). In: Oshima A, Kuroishi T, Tajima K (ed.) Cancer Statistics - Incidence, Mortality, and Survival - 2004. Shinohara Shuppan, Tokyo, pp. 201–217.Google Scholar
  33. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, et al. (1982). Am J Clin Oncol. 5: 649–655.PubMedCrossRefGoogle Scholar
  34. Onishi Y, Yamaura T, Tauchi K, Sakamoto T, Tsukada K, et al. (1998). Biol Pharm Bull. 21: 761–765.PubMedGoogle Scholar
  35. Rogers SN, Ahad SA, Murphy AP. (2007). Oral Oncol. 43: 843–868.PubMedCrossRefGoogle Scholar
  36. Schipper H, Levitt M. (1985). Cancer Treat Rep. 69: 1115–1125.PubMedGoogle Scholar
  37. Seeley C. (1984). Visible Lang. 18: 267–302.Google Scholar
  38. Sprangers MA, Cull A, Bjordal K, Groenvold M, Aaronson NK. (1993). Qual Life Res. 2: 287–295.PubMedCrossRefGoogle Scholar
  39. Sprangers MA, Cull A, Groenvold M, Bjordal K, Blazeby J, et al. (1998). Qual Life Res. 7: 291–300.PubMedCrossRefGoogle Scholar
  40. Statistics and Information Department Ministers Secretariat. (2007). Patient Survey (2005): Vol. 1 (All Japan). Health and Welfare Statistics Association, Tokyo.Google Scholar
  41. Stromborg MF (ed). (1998). Instruments for Clinical Nursing Research. Appleton & Lange, Norwalk, CT.Google Scholar
  42. Tazaki M, Nakane Y, Endo T, Kakikawa F, Kano K, et al. (1998). Jpn J Clin Oncol. 28: 134–141.PubMedCrossRefGoogle Scholar
  43. Toth G, Sakaguchi T, Mikami Y, Hirose H, Tsukuda M. (2005). Auris Nasus Larynx. 32: 175–183.PubMedCrossRefGoogle Scholar
  44. Toth G, Tsukuda M. (2003). Jibiinkoka Tenbo. 46: 368–383.Google Scholar
  45. Toth G, Tsukuda M. (2004). Gan To Kagaku Ryoho. 31: 461–467.PubMedGoogle Scholar
  46. Tsukuma H, Ajiki W, Oshima A. (2004). In: Tajima K, Kuroishi T, Oshima A (ed) Gann Monograph on Cancer Research (2004) Japan Science Society Press, Tokyo, pp. 95–130.Google Scholar
  47. West K. (2002). Quality of Life Group, Newsletter, Issue 2, pp. 2–4.Google Scholar
  48. Weymuller EA Jr., Alsarraf R, Yueh B, Deleyiannis FW, Coltrera MD. (2001). Arch Otolaryngol Head Neck Surg. 127: 489–493.PubMedGoogle Scholar
  49. Yokoyama K, Araki S, Kawakami N, Takeshita T. (1990). Nippon Koshu Eisei Zasshi. 37: 913–918.PubMedGoogle Scholar
  50. Yu F, Takahashi T, Moriya J, Kawaura K, Yamakawa J, et al. (2006). J Int Med Res. 34: 231–239.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media LLC 2010

Authors and Affiliations

  • G. Tóth
  • M. Tsukuda

There are no affiliations available

Personalised recommendations